原題
Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post-hoc analysis of the ENZAMET Phase 3 randomised trial (ANZUP 1304).

Journal: Ann Oncol (CiteScore 2022: 63)
DOI: 10.1016/j.annonc.2025.05.529
PMID: 40403846